HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Serkova, N. J. Articles by Benet, L. Z. Search for Related Content PubMed PubMed Citation Articles by Serkova, N. J. Articles by Benet, L. Z.

Biochemical Mechanisms of Cyclosporine Neurotoxicity

¹ Department of Anesthesiology and ² Department of Pharmacology, University of Colorado Health Sciences Center, Denver, CO 80262; ³ Department of Biopharmaceutical Sciences, University of California, San Francisco, CA 94143

Correspondence: Address correspondence to NS. E-mail Natalie.Serkova{at}uchsc.edu; fax 303-315-1858.

Proper management of chemotoxicity in transplant patients requires detailed knowledge of the biochemical mechanisms underlying immunosuppressant toxicity. Neurotoxicity is one of the most significant clinical side effects of the immunosuppressive undecapeptide cyclosporine, occurring at some degree in up to 60% of transplant patients. The clinical symptoms of cyclosporine-mediated neurotoxicity consist of decreased responsiveness, hallucinations, delusions, seizures, cortical blindness, and stroke-like episodes that mimic those clinical symptoms of mitochondrial encephalopathy. Clinical computed tomography (CT) and magnetic resonance imaging (MRI) studies have revealed a correlation between clinical symptoms of cyclosporine-mediated neurotoxicity and morphological changes in the brain, such as hypodensity of white matter, cerebral edema, metabolic encephalopathy, and hypoxic damages. Paradoxically, in animal models cyclosporine protects the brain from ischemia–reperfusion (I/R) injury. Interestingly, cyclosporine appears to mediate both neurotoxicity (under normoxic conditions) and I/R protection across the same range of drug concentration. Both toxicity and protection might arise from the intersection of cyclosporine with mitochondrial energy metabolism. This review addresses basic biochemical mechanisms of: 1) cyclosporine toxicity in normoxic brain, and 2) its protective effects in the same organ during I/R. The marked and unparallel potential of magnetic resonance spectroscopy (MRS) as a novel quantitative approach to evaluate metabolic drug toxicity is described.

This article has been cited by other articles:

				G. Singh, J. H Rees, and J. W Sander Seizures and epilepsy in oncological practice: causes, course, mechanisms and treatment J. Neurol. Neurosurg. Psychiatry, April 1, 2007; 78(4): 342 - 349. [Abstract] [Full Text] [PDF]

				C. Erxleben, Y. Liao, S. Gentile, D. Chin, C. Gomez-Alegria, Y. Mori, L. Birnbaumer, and D. L. Armstrong Cyclosporin and Timothy syndrome increase mode 2 gating of CaV1.2 calcium channels through aberrant phosphorylation of S6 helices. PNAS, March 7, 2006; 103(10): 3932 - 3937. [Abstract] [Full Text] [PDF]

				S. A. Rizvi and K. Bashir Other therapy options and future strategies for treating patients with multiple sclerosis Neurology, December 28, 2004; 63(12_suppl_6): S47 - S54. [Abstract] [Full Text]